Incretin-Based Therapy and Type 2 Diabetes

Vitamins and Hormones

Volumn 84, Issue C, 2010, Pages 389-413

  Hare, Kristine J ^a   Knop, Filip K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; DRUG DERIVATIVE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1;

ANIMAL; BOOK; DRUG POTENTIATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 78649355826     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381517-0.00015-1     Document Type: Book

References (144)

1. Ahren B., Gomis R., Standl E., Mills D., Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
2. Ahren B., Foley J.E., Ferrannini E., Matthews D.R., Zinman B., Dejager S., Fonseca V.A. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010, 33:730-732.
3. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007, 298:194-206.
4. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
5. Asmar M., Simonsen L., Madsbad S., Stallknecht B., Holst J.J., Bulow J. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 2010, 59:2160-2163.
6. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.P., bboa-Offei B., et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48:5025-5037.
7. Baba A.S., Harper J.M., Buttery P.J. Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2000, 127:173-182.
8. Baggio L.L., Huang Q., Cao X., Drucker D.J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008, 134:1137-1147.
9. Baron A.D., Schaeffer L., Shragg P., Kolterman O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987, 36:274-283.
10. Beck B., Max J.P. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat. Regul. Pept. 1983, 7:3-8.
11. Bergenstal R., Forti A., Chiasson J.-L., Woloschak M., Boldrin M., Leiter L.A., Balena R. Presented at the 69th Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 5-9, 2009 2010, [abstract 58-OR].
12. Blonde L., Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1-5 studies. Diabetes Obes. Metab. 2009, 11(Suppl. 3):26-34.
13. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
14. Bosi E., Lucotti P., Setola E., Monti L., Piatti P.M. Incretin-based therapies in type 2 diabetes: A review of clinical results. Diabetes Res. Clin. Pract. 2008, 82(Suppl. 2):S102-S107.
15. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., Zychma M., Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
16. Buteau J., Roduit R., Susini S., Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42:856-864.
17. Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47:806-815.
18. Carr R.D., Larsen M.O., Winzell M.S., Jelic K., Lindgren O., Deacon C.F., Ahren B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E779-E784.
19. Chacra A.R., Tan G.H., Apanovitch A., Ravichandran S., List J., Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int. J. Clin. Pract. 2009, 63:1395-1406.
20. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
21. Cheung A.T., Dayanandan B., Lewis J.T., Korbutt G.S., Rajotte R.V., Bryer-Ash M., Boylan M.O., Wolfe M.M., Kieffer T.J. Glucose-dependent insulin release from genetically engineered K cells. Science 2000, 290:1959-1962.
22. Damholt A.B., Kofod H., Buchan A.M. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res. 1999, 298:287-293.
23. Deacon C.F. MK-431 (Merck). Curr. Opin. Investig. Drugs 2005, 6:419-426.
24. Deacon C.F., Holst J.J. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. Int. J. Biochem. Cell Biol. 2006, 38:831-844.
25. Deacon C.F., Holst J.J. Saxagliptin: A new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv. Ther. 2009, 26:488-499.
26. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
27. Deacon C.F., Nauck M.A., Meier J., Hucking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000, 85:3575-3581.
28. Ding W.G., Renstrom E., Rorsman P., Buschard K., Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 1997, 46:792-800.
29. Drucker D.J. Glucagon-like peptide 2. J. Clin. Endocrinol. Metab. 2001, 86:1759-1764.
30. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
31. Dube P.E., Brubaker P.L. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm. Metab. Res. 2004, 36:755-760.
32. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9:1173-1179.
33. Ebert R., Nauck M., Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm. Metab. Res. 1991, 23:517-521.
34. Egan J.M., Bulotta A., Hui H., Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab. Res. Rev. 2003, 19:115-123.
35. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J. Endocrinol. 1993, 138:159-166.
36. Elrick H., Stimmler L., Hlad C.J., Rai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964, 24:1076-1082.
37. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267:7402-7405.
38. Fehmann H.C., Goke R., Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 1995, 16:390-410.
39. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 1998, 101:515-520.
40. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
41. Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs 2008, 11:906-917.
42. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
43. Gavin J.R., Alberti K.G.M.M., Davidson M.B., DeFronzo R.A., Drash A., Gabbe S.G., et al. The expert committee on the diagnosis an classification of diabetes mellitus. Diabetes Care 2002, 25(Suppl. 1):S5-S20.
44. Gribble F.M., Williams L., Simpson A.K., Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003, 52:1147-1154.
45. Gromada J., Holst J.J., Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch. 1998, 435:583-594.
46. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., Parker T.G., Huang Q., Drucker D.J., Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
47. Hansen L., Lampert S., Mineo H., Holst J.J. Neural regulation of glucagon-like peptide-1 secretion in pigs. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E939-E947.
48. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004, 53:1326-1335.
49. Hare K.J., Knop F.K., Asmar M., Madsbad S., Deacon C.F., Holst J.J., Vilsboll T. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2009, 94:4679-4687.
50. Hare K.J., Vilsboll T., Asmar M., Deacon C.F., Knop F.K., Holst J.J. The glucagonostatic and insulinotropic effects of glucagon-like peptide-1 contribute equally to its glucose-lowering action. Diabetes 2010, 59:1765-1770.
51. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann. Int. Med. 2005, 143:559-569.
52. Hollander P., Li J., Allen E., Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J. Clin. Endocrinol. Metab. 2009, 94:4810-4819.
53. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87:1409-1439.
54. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47:1663-1670.
55. Holst J.J., Orskov C., Nielsen O.V., Schwartz T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987, 211:169-174.
56. Holst J.J., Bersani M., Johnsen A.H., Kofod H., Hartmann B., Orskov C. Proglucagon processing in porcine and human pancreas. J. Biol. Chem. 1994, 269:18827-18833.
57. Hvidberg A., Nielsen M.T., Hilsted J., Orskov C., Holst J.J. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994, 43:104-108.
58. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am. J. Physiol. 1997, 273:G920-G927.
59. Iwamoto K., Nasu R., Yamamura A., Kothare P.A., Mace K., Wolka A.M., Linnebjerg H. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr. J. 2009, 56:951-962.
60. Jadzinsky M., Pfutzner A., Paz-Pacheco E., Xu Z., Allen E., Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes. Metab. 2009, 11:611-622.
61. Kahn S.E. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am. J. Med. 2000, 108(Suppl. 6a):2S-8S.
62. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
63. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
64. Kielgast U., Holst J.J., Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr. Diabetes Rev. 2009, 5:266-275.
65. Kim J.G., Baggio L.L., Bridon D.P., Castaigne J.P., Robitaille M.F., Jette L., Benquet C., Drucker D.J. Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52:751-759.
66. Kjems L.L., Holst J.J., Volund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
67. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 2008, 24:275-286.
68. Kolterman O.G., Kim D.D., Shen L., Ruggles J.A., Nielsen L.L., Fineman M.S., Baron A.D. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 2005, 62:173-181.
69. Knapper J.M., Puddicombe S.M., Morgan L.M., Fletcher J.M. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat adipose tissue. J. Nutr. 1995, 125:183-188.
70. Krarup T., Saurbrey N., Moody A.J., Kuhl C., Madsbad S. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metabolism 1987, 36:677-682.
71. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.C., Edmondson S., Feeney W.P., He H., Ippolito D.E., Kim D., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
72. Larsson H., Holst J.J., Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol. Scand. 1997, 160:413-422.
73. Layer P., Holst J.J., Grandt D., Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. 1995, 40:1074-1082.
74. Madsbad S., Krarup T., Deacon C.F., Holst J.J. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: A review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:491-499.
75. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 2000, 97:6874-6879.
76. Marre M., Shaw J., Brandle M., Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 2009, 26:268-278.
77. McIntyre N., Holdsworth C.D., Turner D.S. New interpretation of oral glucose tolerance. Lancet 1964, 2:20-21.
78. Meier J.J., Nauck M.A., Schmidt W.E., Gallwitz B. Gastric inhibitory polypeptide: The neglected incretin revisited. Regul. Pept. 2002, 107:1-13.
79. Meier J.J., Gallwitz B., Siepmann N., Holst J.J., Deacon C.F., Schmidt W.E., Nauck M.A. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
80. Meier J.J., Gethmann A., Gotze O., Gallwitz B., Holst J.J., Schmidt W.E., Nauck M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
81. Mentlein R. Dipeptidyl-peptidase IV (CD26)-Role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85:9-24.
82. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., Kubota A., Fujimoto S., Kajikawa M., Kuroe A., Tsuda K., Hashimoto H., et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96:14843-14847.
83. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8:738-742.
84. Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., Habener J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 1986, 261:11880-11889.
85. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987, 79:616-619.
86. Moore B. On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. Biochem. J. 1906, 1:28-38.
87. Mortensen K., Petersen L.L., Orskov C. Colocalization of GLP-1 and GIP in human and porcine intestine. Ann. NY Acad. Sci. 2000, 921:469-472.
88. Mortensen K., Christensen L.L., Holst J.J., Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 2003, 114:189-196.
89. Muller W.A., Faloona G.R., Aguilar-Parada E., Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 1970, 283:109-115.
90. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R., Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986, 63:492-498.
91. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
92. Nauck M.A., Wollschlager D., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553.
93. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., Brodows R., Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 2007, 50:259-267.
94. Nauck M.A., Frid A., Hermansen K., et al. For the LEAD-2 Metformin Study Group: Efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes mellitus. Diabetes Care 2009, 32:84-90.
95. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., During M., Matthews D.R. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
96. Nauck M.A., Ratner R.E., Kapitza C., Berria R., Boldrin M., Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: A double-blind placebo-controlled study. Diabetes Care 2009, 32:1237-1243.
97. Nauck M., Horton E., Andjelkovic M., Javier Ampudia-Blasco F., Boldrin M.N., Balena R. Presented at the 69th Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 5-9 2010, [abstract 60-OR].
98. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., Shannon R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
99. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
100. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E1209-E1215.
101. Oben J., Morgan L., Fletcher J., Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 1991, 130:267-272.
102. Okerson T., Yan P., Stonehouse A., Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am. J. Hypertens. 2010, 23:334-339.
103. Orskov C., Holst J.J., Knuhtsen S., Baldissera F.G., Poulsen S.S., Nielsen O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986, 119:1467-1475.
104. Orskov C., Bersani M., Johnsen A.H., Hojrup P., Holst J.J. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J. Biol. Chem. 1989, 264:12826-12829.
105. Orskov C., Andreasen J., Holst J.J. All products of proglucagon are elevated in plasma from uremic patients. J. Clin. Endocrinol. Metab. 1992, 74:379-384.
106. Pederson R.A., Brown J.C. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978, 103:610-615.
107. Pederson R.A., Kieffer T.J., Pauly R., Kofod H., Kwong J., McIntosh C.H. The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 1996, 45:1335-1341.
108. Perley M.J., Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J. Clin. Invest. 1967, 46:1954-1962.
109. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
110. Pratley R.E., Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001, 44:929-945.
111. Pratley R.E., Jauffret-Kamel S., Galbreath E., Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 2006, 38:423-428.
112. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., Jaspan J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1987, 64:106-110.
113. Reimann F., Gribble F.M. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002, 51:2757-2763.
114. Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2006, 28:1556-1568.
115. Rosenstock J., Baron M.A., Dejager S., Mills D., Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 2007, 30:217-223.
116. Rosenstock J., Reusch J., Bush M., Yang F., Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880-1886.
117. Rosenstock J., Balas B., Charbonnel B., Bolli G.B., Boldrin M., Ratner R., Balena R. Presented at the 69th Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 5-9, 2009 2010, [abstract 62-OR].
118. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., Zdravkovic M., Ravn G.M., Simo R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009, 52:2046-2055.
119. Shah P., Vella A., Basu A., Basu R., Schwenk W.F., Rizza R.A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2000, 85:4053-4059.
120. Simonsen L., Holst J.J., Deacon C.F. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006, 49:706-712.
121. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., Egan J.M. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000, 49:741-748.
122. Tahrani A.A., Piya M.K., Barnett A.H. Saxagliptin: A new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv. Ther. 2009, 26:249-262.
123. Theodorakis M.J., Carlson O., Michopoulos S., Doyle M.E., Juhaszova M., Petraki K., Egan J.M. Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E550-E559.
124. Thim L., Moody A.J. The primary structure of porcine glicentin (proglucagon). Regul. Pept. 1981, 2:139-150.
125. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
126. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Hughes T.E., Michelsen B.K., Holst J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2001, 86:3717-3723.
127. Tracy M.A., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999, 20:1057-1062.
128. Trumper A., Trumper K., Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002, 174:233-246.
129. Verspohl E.J. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol. Ther. 2009, 124:113-138.
130. Vilsboll T., Holst J.J. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004, 47:357-366.
131. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
132. Vilsboll T., Krarup T., Madsbad S., Holst J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002, 45:1111-1119.
133. Vilsboll T., Krarup T., Madsbad S., Holst J.J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114:115-121.
134. Vilsboll T., Agerso H., Lauritsen T., Deacon C.F., Aaboe K., Madsbad S., Krarup T., Holst J.J. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul. Pept. 2006, 137:168-172.
135. Wang Y., Perfetti R., Greig N.H., Holloway H.W., DeOre K.A., Montrose-Rafizadeh C., Elahi D., Egan J.M. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 1997, 99:2883-2889.
136. Wang M., Matheson S., Picard J., Pezzullo J. Presented at the 69th Scientific Sessions of the American Diabetes Association 2009, [abstract 553-P]. New Orleans, LA, June 5-9.
137. Wasada T., McCorkle K., Harris V., Kawai K., Howard B., Unger R.H. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J. Clin. Invest. 1981, 68:1106-1107.
138. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
139. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 1996, 81:327-332.
140. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
141. Yip R.G., Boylan M.O., Kieffer T.J., Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139:4004-4007.
142. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359:824-830.
143. Zhou J., Wang X., Pineyro M.A., Egan J.M. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999, 48:2358-2366.
144. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.